posted on 2024-07-02, 07:40authored byYuting Meng, Zheyue Shu, Xueyao Wang, Liang Hong, Baohua Wang, Jingjing Jiang, Kangxin He, Qingyi Cao, Fan Shi, Hai Wang, Lan Gong, Hongyan Diao
Supplementary Table 3 shows primer sequences
Funding
National Key Research and Development Program of China (NKPs)
Fundamental Research Funds for Central Universities of the Central South University (Fundamental Research Funds for the Central Universities of Central South University)
Research project of Jinan Microecological Biomedicine Shandong Laboratory
Public Welfare Foundation of Zhejiang Science and Technology Agency
History
ARTICLE ABSTRACT
Hepatitis B viral (HBV) persistent infection plays a significant role in hepatocellular carcinoma (HCC) tumorigenesis. Many studies have revealed the pivotal roles of N6-methyladenosine (m6A) in multiple cancers, while the regulatory mechanism in stemness maintenance of HBV persistent infection-related HCC remains elusive. Here, we demonstrated that the level of m6A modification was downregulated by HBV in HBV-positive HCC, through enhanced stability of ALKBH5 mRNA. More specifically, we also identified that ALKBH5 mRNA was functionally required for the stemness maintenance and self-renewal in the HBV-positive HCC, but dispensable in HBV-negative HCC. Mechanistically, ALKBH5 demethylated the m6A modification in the 3′ untranslated region of the oncogenic gene SNAI2 to prevent the recognition of YTHDF2 therewith stabilize SNAI2 transcripts, contributing to cancer stem cell traits in HBV-positive HCC. Moreover, the expression of SNAI2 reversed the suppression of stemness properties by knocking down ALKBH5. In addition, ALKBH5/SNAI2 axis accelerates tumor immune evasion through activated ligand of immune checkpoint CD155. Our study unveiled that the ALKBH5 induces m6A demethylation of the SNAI2 as a key regulator in HBV-related HCC, and identifies the function of ALKBH5/SNAI2/YTHDF2 axis in promoting the stem-like cells phenotype and immune escape during HBV infection.
HBV promotes HCC stemness maintenance through elevate m6A modification of SNAI2 in an ALKBH5-YTHDF2–dependent manner and increases the expression of the ligand of immune checkpoint CD155.